ResMed is a global medical technology and software company that has carved out a dominant niche in the rather unglamorous, yet critically important, world of sleep and respiratory care. Essentially, they are the silent guardians of nocturnal respiration, ensuring humanity doesn't accidentally self-asphyxiate in its slumber or struggle through the day gasping for air. The company’s core business revolves around developing and manufacturing cloud-connected medical devices for treating sleep-disordered breathing, like sleep apnea, and chronic respiratory diseases such as COPD.

Their product portfolio is a symphony of pressurized air and plastic tubing, featuring Continuous Positive Airway Pressure (CPAP) machines, masks, and accessories that are indispensable for millions. Beyond the hardware, ResMed is a pioneer in digital health, offering cloud-based software platforms like AirView and myAir that transform snorts into data points, enabling remote monitoring and improving patient adherence to therapy. This integrated ecosystem, often described as a "razor and blade" model, generates recurring revenue from both device sales and the constant need for replacement masks and supplies.

Operating in over 140 countries, ResMed boasts a significant global footprint, with major markets in the Americas, Europe, and Asia-Pacific. Their competitive advantage stems from a relentless focus on R&D, an extensive patent portfolio (over 9,000 patents, because who knew there were so many ways to design a comfortable air delivery system?), and a vast installed base of connected devices that generate invaluable clinical data. This data-driven approach helps them maintain a substantial market share in the sleep apnea device sector, estimated to be around 62%.

The company recently navigated a rather unique market dynamic when a major competitor, Philips Respironics, initiated a massive recall of its CPAP devices, creating an ethically complex, yet undeniable, surge in demand for ResMed's products. This event, while a boon for ResMed, also highlighted the critical nature of these devices and the ongoing debates around supply chain resilience and market dominance in a sector where the stakes are literally life and breath. ResMed has also been involved in patent disputes, notably securing victories against New York University regarding its AutoSet and AutoRamp features.